Pdl Biopharma, Inc. Watch

from 10-K 2 pages Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

from 10-K 2 pages Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

from 8-K 76 pages Pdl Biopharma, Inc. as Issuer and the Bank of New York Mellon Trust Company, N.A. as Trustee Supplemental Indenture Dated as of September 17, 2019 2.75% Convertible Senior Notes Due 2024

from 8-K 44 pages Pdl Biopharma, Inc. Debt Securities Indenture Dated as of September 17, 2019 the Bank of New York Mellon Trust Company, N.A., as Trustee

from S-3 44 pages Pdl Biopharma, Inc. Debt Securities Indenture Dated as of [ ] [ ], as Trustee

from 8-K 9 pages Pdl Biopharma, Inc. 2.75% Convertible Senior Note Due 2021

from 8-K 64 pages Pdl Biopharma, Inc. as Issuer and the Bank of New York Mellon Trust Company, N.A. as Trustee Supplemental Indenture Dated as of November 22, 2016 2.75% Convertible Senior Notes Due 2021 1

from 8-K 44 pages Pdl Biopharma, Inc. Debt Securities Indenture Dated as of November 22, 2016 the Bank of New York Mellon Trust Company, N.A., as Trustee

from S-3 43 pages Definitions and Incorporation by Reference

from 10-K 12 pages Agreement

from 8-K 66 pages Pdl Biopharma, Inc. as Issuer and the Bank of New York Mellon Trust Company, N.A. as Trustee Supplemental Indenture Dated as of February 12, 2014 $300,000,000 4.00% Convertible Senior Notes Due 2018

from 8-K 44 pages Definitions and Incorporation by Reference

from S-3ASR 44 pages Definitions and Incorporation by Reference

from S-3ASR 2 pages Certificate of Amendment of Restated Certificate of Incorporation of Pdl Biopharma, Inc

from 8-K 84 pages Pdl Biopharma, Inc. 2.875% Series 2012 Convertible Senior Notes Due February 15, 2015 Indenture Dated as of January 5, 2012 the Bank of New York Mellon Trust Company, N. A. as Trustee

from 10-Q 46 pages Pdl Biopharma, Inc. Debt Securities Indenture Dated as of May 16, 2011 the Bank of New York Mellon Trust Company, N.A., as Trustee

from 8-K 59 pages PDL Biopharma, Inc. as Issuer and the Bank of New York Mellon Trust Company, N.A. as Trustee Supplemental Indenture Dated as of May 16, 2011 $155,250,000 3.75% Convertible Senior Notes Due 2015

from S-3ASR 2 pages Common Stock Pdl Biopharma, Inc. See Heverse for Certain Definitions Incorporated Under the Laws of the State of Delaware This Certifies That Specimen Is the Registered Holder of Fully Paid and Nonassessable Shares of Common Stock $ 01 Par Value Per Share, of Pdl Biopharma, Inc. Transferable Only on the Books of the Corporation by the Holders Hereof, or by Attorney or Legal Representative, Upon Surrender of This Certificate Properly Endorsed. in Witness Whereof, the Said Corporation Has Caused This Certificate to Be Signed by Its Duly Authorized Office and Its Corporate Seal to Be Hereunto Affixed Countersigned and Registered Mellon Investor Services LLC Transfer Agent and Register Authorized Signature

from S-3ASR 46 pages Pdl Biopharma, Inc. Debt Securities Indenture Dated as of [ ] the Bank of New York Mellon Trust Company, N.A., as Trustee

from 10-Q 84 pages Pdl Biopharma, Inc. 2.875% Convertible Senior Notes Due February 15, 2015 Indenture Dated as of November 1, 2010 the Bank of New York Mellon Trust Company, N. A. as Trustee